{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 155, "pageCount": 415, "prevPage": 154, "nextPage": 156, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide uses Q&A transcripts to expose the risks associated with the drug.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 0.95, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/155", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-155", "components": [ { "bbox": null, "kind": "callout", "text": "Trial investigator #6 stated that diazoxide can be fatal and is contraindicated in patients with elevated pulmonary pressures - common in PWS patients due to obesity and diabetes, both of which greatly increase risk of increased pulmonary hypertension", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2a2-c174f0d7ea87", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.22, "w": 0.86, "x": 0.07, "y": 0.72 }, "kind": "paragraph", "text": "If using Vykat, would require an echocardiogram before and two weeks after, and then every 6-12 months\nQ: “So, you said when you do it in infancy, do an echo before. And how often do you do an echo while they’re on diazoxide?”\nA: “You do an echo before you can start it. And you measure pulmonary pressures, and then you do it again at day ten. By that point, if you’re going to have a problem, the pulmonary pressure should have changed by day ten. And then we tend to do it every couple of months just to be on the safe side until they’re about eight months. In ones with Prader-Willi, I would be wanting an echo before and then two weeks after. And then to be honest, I think because we’re still not sure how this will go, whereas in diazoxide for hyperinsulinism, we’ve got a good idea of what happens, I would probably do them six months to annually to be on the safe side.” -Trial investigator, pediatric endocrinologist", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "87208a48-5d49-46a2-b5a6-493cc58704e8", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.45 }, "kind": "paragraph", "text": "“Devastating” risk with diazoxide in infants with high pulmonary pressures; “they don’t start diazoxide”\nA: “I would worry about that because we know that it happens in infants, and that’s why they have to stop using diazoxide in this condition called hyperinsulinism.”\nQ: “How often does it happen in hyperinsulinism in infants? The pulmonary edema.”\nA: “We probably treat about 20 to 30 infants a year. And it maybe only happens in 1 in 100 or something. It’s not that often, but it can be devastating. It can cause a real problem. So, that would be my worry. Basically, if we have a baby, he’s got high pulmonary pressures, they don’t start diazoxide.” - Trial investigator, pediatric endocrinologist", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "ba3ed27f-a2d9-4a97-964b-7b3652f5ae06", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“that’s why they have to stop using diazoxide...it can be devastating...that would be my worry.” — Trial investigator #6", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2a2-c543210c116f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": { "numbered": true }, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c4bc9de3-66d1-474b-837a-5a633e41b518", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "Trial investigator #6 stated that diazoxide can be fatal and is contraindicated in patients with elevated pulmonary pressures - common in PWS patients due to obesity and diabetes, both of which greatly increase risk of increased pulmonary hypertension - “that’s why they have to stop using diazoxide...it can be devastating...that would be my worry.” The investigator indicated that ongoing echocardiograms are mandatory if using Vykat - “an echo before you can start it...and you measure pulmonary pressures...and then we tend to do it every couple of months...with Prader-Willi, I would be wanting an echo before and then two weeks after...and then to be honest...because we’re still not sure how this will go...I would probably do them six months to annually.”", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "6719cf15-9a56-4607-b830-1744735b2825", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }